Biotech investing is typically associated with binary risk: a drug either works or it does not. Most deep-value investors avoid the sector entirely for this reason. But RTW Biotech Opportunities is not a biotech company – it is a closed-end investment trust that holds a diversified portfolio of biotech positions, and it was trading at a substantial discount to its net asset value.
That discount is what TVISIL’s cheap-asset screen found. The result: +151% total return.
What Is RTW Biotech Opportunities?
RTW Biotech Opportunities (LSE: RTW) is a London-listed closed-end investment trust managed by RTW Investments, a specialist life sciences investment firm based in New York. The trust invests in a diversified portfolio of public and private biotech and life sciences companies at various stages of development.
As a closed-end fund listed on the London Stock Exchange, RTW’s share price is determined by supply and demand in the market, not by the underlying net asset value of its portfolio. This creates the potential for the trust to trade at a discount to NAV – which is exactly the situation TVISIL’s screens identified.
What the TVISIL Screen Found
Significant discount to net asset value: At TVISIL’s entry, RTW’s shares were trading at a meaningful discount to the reported NAV of its underlying portfolio. For a trust managed by a reputable specialist with a clear and transparent portfolio, this discount represented straightforward asset mispricing.
Quality of the manager: RTW Investments has a strong track record in life sciences investing. The discount was driven by general investor risk aversion toward biotech following a sector-wide derating, not by any specific concerns about RTW’s portfolio quality or management capability.
Diversification reduces binary risk: Unlike investing in a single biotech company, RTW holds a diversified portfolio of positions across different therapeutic areas and development stages. This substantially reduces the binary outcome risk that makes single-stock biotech investing unattractive for a value process.
Discount narrowing as a return driver: Closed-end fund discounts tend to narrow over time when the manager performs well, when buybacks are executed, or when broader sector sentiment improves. TVISIL identified all three as plausible paths to re-rating.
The Outcome
+151% total return from the TVISIL entry to exit. The position is fully closed and documented in the TVISIL historical portfolio with entry date, exit date, and total percentage return.
The Lesson
RTW Biotech Opportunities shows that cheap-asset investing is not limited to industrial companies or net-nets. Closed-end investment trusts trading at discounts to NAV are a classic deep-value opportunity, and one that is frequently overlooked by investors who focus only on operating businesses. TVISIL’s process is designed to find mispriced assets wherever they appear – across sectors, asset classes, and geographies.
See every TVISIL position – open, evaluating and closed – at www.valueinvestingsage.com/pricing. Plans from $20 trial to $549/year Diamond.
TVISIL is an educational model portfolio. Not personalised investment advice. All investing involves risk including permanent capital loss. Past performance does not guarantee future results.